Clovis Oncology Inc (CLVS)

70.32
NASDAQ : Health Care
Prev Close 68.53
Day Low/High 68.54 / 70.98
52 Wk Low/High 11.57 / 74.94
Avg Volume 2.32M
Exchange NASDAQ
Shares Outstanding 44.63M
Market Cap 3.06B
EPS -9.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Goldman Sachs Raises Clovis Oncology Price Target to $75

Goldman Sachs Raises Clovis Oncology Price Target to $75

Clovis Oncology closed trading below $67 on Tuesday.

6 Stocks Trending Up With Major Volume

6 Stocks Trending Up With Major Volume

Here's a technical look at how to play a number of stocks trending higher with strong volume.

AstraZeneca Takes PARP Inhibitor Fight to Rival Tesaro with Strong Ovarian Cancer Study Results

AstraZeneca Takes PARP Inhibitor Fight to Rival Tesaro with Strong Ovarian Cancer Study Results

AstraZeneca's PARP inhibitor Lynparza delayed the recurrence of ovarian cancer by more than two years compared to a placebo.

Clovis Oncology Presents New Data From Phase 2 Studies Of Rucaparib In Advanced Ovarian Cancer At 2017 SGO Annual Meeting On Women's Cancer

Clovis Oncology Presents New Data From Phase 2 Studies Of Rucaparib In Advanced Ovarian Cancer At 2017 SGO Annual Meeting On Women's Cancer

Clovis Oncology, Inc. (NASDAQ:CLVS) announced new data from parts 1 and 2 of the ongoing ARIEL2 Phase 2 study being presented today at the 2017 Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer in...

Clovis Oncology Announces 2016 Operating Results

Clovis Oncology Announces 2016 Operating Results

Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter and year ended December 31, 2016, and provided an update on the Company's clinical development programs and regulatory outlook for 2017.

Clovis, Tesaro Soar on Astrazeneca Phase Three News

Clovis, Tesaro Soar on Astrazeneca Phase Three News

AstraZeneca shares, meanwhile, were less-than-moved by the news.

Morgan Stanley, Twitter, Tesaro: Doug Kass' Views

Morgan Stanley, Twitter, Tesaro: Doug Kass' Views

Doug Kass shares his thoughts on boosts to financials, and discusses what M&A speculation is doing to biotechs.

Clovis Oncology Inc Reaches Analyst Target Price

Clovis Oncology Inc Reaches Analyst Target Price

In recent trading, shares of Clovis Oncology Inc have crossed above the average analyst 12-month target price of $63.71, changing hands for $65.13/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Clovis Oncology To Announce Fourth Quarter/Year-End 2016 Financial Results And Host Webcast Conference Call On February 22

Clovis Oncology To Announce Fourth Quarter/Year-End 2016 Financial Results And Host Webcast Conference Call On February 22

Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its fourth quarter/year-end 2016 financial results on Wednesday, February 22, 2017, after the close of the U.

Biotech Tesaro Climbs on Takeout Reports

Biotech Tesaro Climbs on Takeout Reports

The company's shares were up 14% on rumors that it is working with investment banks to consider a sale.

4 Biotech Names That Could Be M&A Targets

4 Biotech Names That Could Be M&A Targets

Animal health and oncology deal activity is heating up in 2017.

Clovis Oncology To Present At The 35th Annual J.P. Morgan Healthcare Conference

Clovis Oncology To Present At The 35th Annual J.P. Morgan Healthcare Conference

Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its Chief Executive Officer and President, Patrick J.

Clovis Oncology Announces Exercise In Full Of Underwriters' Option To Purchase Additional Shares Of Common Stock

Clovis Oncology Announces Exercise In Full Of Underwriters' Option To Purchase Additional Shares Of Common Stock

Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that the underwriters of its recently announced public offering of its common stock have exercised in full their option to purchase an additional 750,000 shares.

Clovis Oncology Announces Upsizing And Pricing Of Public Offering Of Common Stock

Clovis Oncology Announces Upsizing And Pricing Of Public Offering Of Common Stock

Clovis Oncology, Inc. (NASDAQ:CLVS) announced today the pricing of an underwritten public offering of 5,000,000 shares of its common stock at $41.

Clovis Oncology Announces Proposed Offering Of Common Stock

Clovis Oncology Announces Proposed Offering Of Common Stock

Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that it has commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of approximately $175 million.

17 Thoughts on Biotech Stocks to Kick Off 2017

17 Thoughts on Biotech Stocks to Kick Off 2017

Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.

Noteworthy Monday Option Activity: CLVS, GTY, BEAT

Noteworthy Monday Option Activity: CLVS, GTY, BEAT

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Clovis Oncology Inc , where a total of 10,313 contracts have traded so far, representing approximately 1.0 million underlying shares. That amounts to about 75.4% of CLVS's average daily trading volume over the past month of 1.4 million shares.

Big-Cap Tech Names, Biotechs, Oils Lifting Market

Big-Cap Tech Names, Biotechs, Oils Lifting Market

The number of new 12-month highs has climbed to 240.

Clovis Oncology Gets FDA Approval for New Ovarian Cancer Drug

Clovis Oncology Gets FDA Approval for New Ovarian Cancer Drug

A new treatment has been approved by the FDA for treatment of ovarian cancer. The treatment is made by Clovis Oncology.

Clovis Oncology Secures FDA Approval for New Ovarian Cancer Drug

Clovis Oncology Secures FDA Approval for New Ovarian Cancer Drug

Clovis will market the new drug under the brand name Rubraca.

Newman Ferrara LLP Announces Corporate Governance Investigation Of Clovis Oncology Inc.

Newman Ferrara LLP Announces Corporate Governance Investigation Of Clovis Oncology Inc.

Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Clovis Oncology Inc.

First Week of July 2017 Options Trading For Clovis Oncology (CLVS)

First Week of July 2017 Options Trading For Clovis Oncology (CLVS)

Investors in Clovis Oncology Inc saw new options become available this week, for the July 2017 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Robbins Arroyo LLP: Clovis Oncology, Inc. (CLVS) Misled Shareholders According To A Recently Filed Lawsuit

Robbins Arroyo LLP: Clovis Oncology, Inc. (CLVS) Misled Shareholders According To A Recently Filed Lawsuit

Shareholder rights law firm Robbins Arroyo LLP announces that a lawsuit was filed against Clovis Oncology, Inc.

CLVS Crosses Above Average Analyst Target

CLVS Crosses Above Average Analyst Target

In recent trading, shares of Clovis Oncology Inc have crossed above the average analyst 12-month target price of $33.14, changing hands for $33.98/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.